PharmaCorp Files Q3 2024 Financial Statements and MD&A
PharmaCorp Files Q3 2024 Financial Statements and MD&A
SASKATOON, Saskatchewan, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. ("PharmaCorp" or the "Corporation") (TSXV: PCRX) is pleased to announce the filing on SEDAR+ of its unaudited financial statements together with associated MD&A for the three and nine months ended September 30, 2024. To review the Corporation's Q3 2024 unaudited financial statements and associated MD&A please visit SEDAR+ at .
薩斯卡通，薩斯喀徹溫，2024年11月26日（環球新聞社）- PHARMACORP RX INC.（「PharmaCorp」或「公司」）（tsxv: PCRX）很高興宣佈已在SEDAR+上提交其截至2024年9月30日的三個和九個月未經審計的基本報表，包括相關的管理討論與分析。要查看公司2024年第三季度未經審計的基本報表和相關的管理討論與分析，請訪問SEDAR+ .
About PharmaCorp Rx Inc.
關於PharmaCorp Rx Inc.
PharmaCorp currently operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada branded pharmacies as they come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The Corporation will also acquire independently owned non-PharmaChoice Canada bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner. PharmaCorp shares trade on the TSX Venture Exchange under the symbol: PCRX.
PharmaCorp目前在加拿大經營三家PharmaChoice品牌藥店，並將繼續收購PharmaChoice Canada品牌藥店，以便與其與PharmaChoice Canada的戰略聯盟協議相結合。該公司還將收購加拿大獨立擁有的非PharmaChoice Canada品牌藥店，之後將繼續在PharmaChoice Canada品牌下運營這些收購的藥店。PharmaCorp股票在tsx創業公司交易所上交易，代碼爲PCRX。
For further information, contact:
如需更多信息，請聯繫：
Mr. Alan Simpson
Suite #203, 303 Wellman Lane, Saskatoon, SK S7T 0J1
Tel: (306) 536-3771
Alan Simpson先生
套房#203, 303 Wellman Lane, Saskatoon, Sk S7萬億 0J1
電話：(306) 536-3771
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX Venture交易所和其監管服務提供商（如該交易所的政策中所定義的）均不接受此新聞稿的充分性或準確性的責任。
